Table 2 Change in phosphorylated AKT (pS473_AKT) post-treatment with lapatinib and/or trastuzumab in HER2-positive breast tumours18
Patient no. | Treatment regimen | pS473_AKT | Â |
|---|---|---|---|
Fold change post-treatment | pCR | ||
21 | Lapatinib | 1.1 | No |
42 | Lapatinib | 1.3 | No |
3 | Lapatinib | 1.0 | No |
45 | Lapatinib | 1.5 | No |
85 | Lapatinib | 2.2 | Yes |
185 | Lapatinib | 1.6 | No |
369 | Lapatinib | 1.8 | Yes |
7 | Lapatinib | 1.7 | No |
8 | Lapatinib | 3.7 | No |
204 | Lapatinib | 1.3 | No |
491 | Lapatinib | 0.7 | No |
504 | Lapatinib | 1.1 | Yes |
507 | Lapatinib | 0.7 | Yes |
81 | Trastuzumab | 0.5 | Yes |
82 | Trastuzumab | 1.0 | Yes |
321 | Trastuzumab | 0.4 | Yes |
365 | Trastuzumab | 5.0 | Yes |
24 | Trastuzumab | 4.1 | Yes |
364 | Trastuzumab | 0.9 | No |
5 | Trastuzumab | 0.6 | Yes |
31 | Trastuzumab | 0.9 | Yes |
84 | Trastuzumab | 0.6 | No |
202 | Trastuzumab | 0.5 | No |
367 | Trastuzumab | 0.4 | Yes |
6 | Trastuzumab | 0.6 | No |
39 | Trastuzumab | 0.3 | No |
193 | Trastuzumab | 3.9 | No |
412 | Trastuzumab | 3.7 | Yes |
442 | Trastuzumab | 0.2 | No |
506 | Trastuzumab | 1.2 | Yes |
23 | Trast + Lapatinib | 4.1 | Yes |
44 | Trast + Lapatinib | 9.0 | No |
30 | Trast + Lapatinib | 2.7 | Yes |
363 | Trast + Lapatinib | 0.5 | Yes |
303 | Trast + Lapatinib | 0.7 | Yes |
88 | Trast + Lapatinib | 1.2 | Yes |
221 | Trast + Lapatinib | 1.1 | Yes |
373 | Trast + Lapatinib | 0.9 | Yes |
501 | Trast + Lapatinib | 1.3 | Yes |